New aspects of natural products in drug discovery

Trends in Microbiology

Volumn 15, Issue 6, 2007, Pages 279-289

  Lam, Kin S ^a  

^a Nereus Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXYNOJIRIMYCIN; AMRUBICIN; AMYLIN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ASCOMYCIN; BIAPENEM; CARBAPENEM; CASPOFUNGIN; COMPACTIN; DAPTOMYCIN; DOXORUBICIN; ERTAPENEM; ERYTHROMYCIN; FULVESTRANT; GALANTAMINE; IMMUNOSUPPRESSIVE AGENT; INCRETIN; MICAFUNGIN; MIGLUSTAT; MYCOPHENOLIC ACID; NATURAL PRODUCT; NITISINONE; OMEGACIN; PACLITAXEL; PIMECROLIMUS; PNEUMOCANDIN DERIVATIVE; RAPAMYCIN; TELITHROMYCIN; THIENAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ATOPIC DERMATITIS; BACTERIAL INFECTION; BIOSYNTHESIS; CANCER; CHEMICAL MODIFICATION; DERIVATIZATION; DIABETES MELLITUS; DNA SEQUENCE; DRUG DESIGN; DRUG INDICATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DYSLIPIDEMIA; ENZYME ACTIVITY; GAUCHER DISEASE; GENE SEQUENCE; GENOMICS; GRAFT REJECTION; HIGH THROUGHPUT SCREENING; HUMAN; INFECTION; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TYROSINEMIA;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; BACTERIA; BIOLOGICAL FACTORS; BIOTECHNOLOGY; CLINICAL TRIALS; COMMUNICABLE DISEASES; DRUG EVALUATION, PRECLINICAL; FUNGI; HUMANS;

EID: 34249811180     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2007.04.001     Document Type: Review

References (84)

1. Newman D.J., et al. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. 66 (2003) 1022-1037
2. Butler M.S. The role of natural product chemistry in drug discovery. J. Nat. Prod. 67 (2004) 2141-2153
3. Butler M.S. Natural products to drugs: natural product derived compounds in clinical trials. Nat. Prod. Rep. 22 (2005) 162-195
4. Eldridge G.R., et al. High-throughput method for the production and analysis of large natural product libraries for drug discovery. Anal. Chem. 74 (2002) 3963-3971
5. Harrigan G.G., and Goetz G.H. Chemical and biological integrity in natural product screening. Comb. Chem. High Throughput Screen. 8 (2005) 529-534
6. Koehn F.E., and Carter G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 4 (2005) 206-220
7. Leeds J.A., et al. Recent developments in antibacterial drug discovery: microbe-derived natural products - from collection to the clinic. Expert Opin. Investig. Drugs 15 (2006) 211-226
8. Exarchou V., et al. LC-NMR coupling technologies: recent advancements and applications in natural products analysis. Magn. Reson. Chem. 43 (2005) 681-687
9. Exarchou V., et al. Hyphenated chromatographic techniques for the rapid screening and identification of antioxidants in methanolic extracts of pharmaceutically used plants. J. Chromatogr. A. 1112 (2006) 293-302
10. Tatsis E.C., et al. Identification of the major constituents of Hypericum perforatum by LC/SPE/NMR and/or LC/MS. Phytochemistry 68 (2007) 383-393
11. Busti E., et al. Antibiotic-producing ability by representatives of a newly discovered linage of actinomycetes. Microbiology 152 (2006) 675-683
12. Saintpierre-Bonaccio D., et al. Amycolatopsis plumensis sp. nov., a novel bioactive actinomycete isolated from a New-Caledonian brown hypermagnesian ultramafic soil. Int. J. Syst. Evol. Microbiol. 55 (2005) 2057-2061
13. Strobel G. Harnessing endophytes for industrial microbiology. Curr. Opin. Microbiol. 9 (2006) 240-244
14. Davis K.E.R., et al. Effects of growth medium, inoculum size, and incubation time on culturability and isolation of soil bacteria. Appl. Environ. Microbiol. 71 (2005) 826-834
15. Tan G.Y.A., et al. Exploration of Amycolatopsis diversity in soil using genus-specific primers and novel selective media. Syst. Appl. Microbiol. 29 (2006) 557-569
16. Bode H.B., and Müller R. Analysis of myxobacterial secondary metabolism goes molecular. J. Ind. Microbiol. Biotechnol. 33 (2006) 577-588
17. Jensen P.R., et al. Culturable marine actinomycete diversity from tropical Pacific Ocean sediments. Environ. Microbiol. 7 (2005) 1039-1048
18. Ward A.C., and Bora N. Diversity and biogeography of marine actinobacteria. Curr. Opin. Microbiol. 9 (2006) 279-286
19. Pathom-aree W., et al. Diversity of actinomycetes isolated from Challenger Deep sediment (10,898 m) from the Mariana Trench. Extremophiles 10 (2006) 181-189
20. Fenical W., and Jensen P.R. Developing a new resource for drug discovery: marine actinomycete bacteria. Nat. Chem. Biol. 2 (2006) 666-673
21. Lam K.S. Discovery of novel metabolites from marine actinomycetes. Curr. Opin. Microbiol. 9 (2006) 245-251
22. Kwon H.C., et al. Marinomycins A-D, antitumor-antibiotics of a new structure class from a marine actinomycete of the recently discovered genus "Marinispora". J. Am. Chem. Soc. 128 (2006) 1622-1632
23. Bugni T.S., and Ireland C.M. Marine-derived fungi: a chemically and biologically diverse group of microorganisms. Nat. Prod. Rep. 21 (2004) 143-163
24. Bhadury P., et al. The current status of natural products from marine fungi and their potential as anti-infective agents. J. Ind. Microbiol. Biotechnol. 33 (2006) 325-337
25. Paterson I., and Anderson E.A. The renaissance of natural products as drug candidates. Science 310 (2005) 451-453
26. Ortholand J.Y., and Ganesan A. Natural products and combinatorial chemistry: back to the future. Curr. Opin. Chem. Biol. 8 (2004) 271-280
27. Ganesan A. Natural products as a hunting ground for combinatorial chemistry. Curr. Opin. Biotechnol. 15 (2004) 584-590
28. Butler M.S., and Buss A.D. Natural products - the future scaffolds for novel antibiotics. Biochem. Pharmacol. 71 (2006) 919-929
29. Stein G.E., and Craig W.A. Tigecycline: a critical analysis. Clin. Infect. Dis. 43 (2006) 518-524
30. Van Bambeke F. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Curr. Opin. Investig. Drugs 7 (2006) 740-749
31. Muller M. Chemical diversity through biotransformation. Curr. Opin. Biotechnol. 15 (2004) 591-598
32. Lamb S.S., and Wright G.D. Accessorizing natural products: adding to nature's toolbox. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 519-520
33. Naidu B.N., et al. Synthesis and antibacterial activity of nocathiacin I analogues. Bioorg. Med. Chem. Lett. 16 (2006) 3545-3549
34. Fu X., et al. Diversifying vancomycin via chemoenzymatic strategies. Org. Lett. 7 (2005) 1513-1515
35. Grünewald J., and Marahiel M.A. Chemoenzymatic and template-directed synthesis of bioactive macrocyclic peptides. Microbiol. Mol. Biol. Rev. 70 (2006) 121-146
36. Zheng W., et al. Macrocyclic ketone analogues of halichondrin B. Bioorg. Med. Chem. Lett. 14 (2004) 5551-5554
37. Wender P.A., et al. Function oriented synthesis: the design, synthesis, PKC binding and translocation activity of a new bryostatin analog. Curr. Drug. Discov. Technol. 1 (2004) 1-11
38. Shaw S.J., et al. Toward understanding how the lactone moiety of discodermolide affects activity. J. Am. Chem. Soc. 127 (2005) 6532-6533
39. Charest M.G., et al. A convergent enantioselective route to structurally diverse 6-deoxytetracycline antibiotics. Science 308 (2005) 395-398
40. Balamurugan R., et al. Design of compound libraries based on natural product scaffolds and protein structures similarity clustering (PSSC). Mol. Biosyst. 1 (2005) 36-45
41. Sánchez C., et al. Combinatorial biosynthesis of antitumor indolocarbazole compounds. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 461-466
42. Floss H.G. Combinatorial biosynthesis - potential and problems. J. Biotechnol. 124 (2006) 242-257
43. Baltz R.H. Combinatorial biosynthesis of novel antibiotics and other secondary metabolites in actinomycetes. SIM News 56 (2006) 148-158
44. Lamb S.S., et al. Biosynthesis of sulfated glycopeptide antibiotics by using the sulfotransferase StaL. Chem. Biol. 13 (2006) 171-181
45. Zazopoulos E., et al. A genomics-guided approach for discovering and expressing cryptic metabolic pathways. Nat. Biotechnol. 21 (2003) 187-190
46. Farnet C.M., and Zazopoulos. Improving drug discovery from microorganisms. In: Zhang L., and Demain A.L. (Eds). Natural Products: Drug Discovery and Therapeutic Medicine (2005), Humana Press 95-106
47. Van Lanen S.G., and Shen B. Microbial genomics for the improvement of natural product discovery. Curr. Opin. Microbiol. 9 (2006) 252-260
48. Keller N.P., et al. Fungal secondary metabolism - from biochemistry to genomics. Nat. Rev. Microbiol. 3 (2005) 937-947
49. Bode H.B., et al. Big effects from small changes: possible ways to explore nature's chemical diversity. ChemBioChem 3 (2002) 619-627
50. Kegler C., et al. Establishment of a real-time PCR protocol for expression studies of secondary metabolite biosynthetic gene clusters in the G/C-rich myxobacterium Sorgangium cellulosum So ce56. J. Biotechnol. 121 (2006) 201-212
51. Gullo V.P., et al. Drug discovery from natural products. J. Ind. Microbiol. Biotechnol. 33 (2006) 523-531
52. Denduluri N., et al. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest. New Drugs 25 (2007) 63-67
53. Duran I., et al. A Phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br. J. Cancer 95 (2006) 1148-1154
54. Chauhan D., et al. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br. J. Cancer 95 (2006) 961-965
55. Nicholson B., et al. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 17 (2006) 25-31
56. He H. Mannopeptimycins, a novel class of glycopeptide antibiotics active against Gram-positive bacteria. Appl. Microbiol. Biotechnol. 67 (2005) 444-452
57. Banskota A.H., et al. Genomic analysis lead to novel secondary metabolites. Part 3. ECO-0501, a novel antibacterial of a new class. J. Antibiot. (Tokyo) 59 (2006) 533-542
58. Clardy J., and Walsh C. Lessons from natural molecules. Nature 432 (2004) 829-837
59. Bérdy J. Bioactive microbial metabolites. J. Antibiot. (Tokyo) 58 (2005) 1-26
60. Lee M.L., and Schneider G. Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries. J. Comb. Chem. 3 (2001) 284-289
61. Bajorath J. Chemoinformatics methods for systematic comparison of molecules from natural and synthetic sources and design of hybrid libraries. J. Comput. Aided Mol. Des. 16 (2002) 431-439
62. Feher M., and Schmidt J.M. Property distributions: differences between drugs, natural products and molecules from combinatorial chemistry. J. Chem. Inf. Comput. Sci. 43 (2003) 218-227
63. Bibb M.J. Regulation of secondary metabolism in streptomycetes. Curr. Opin. Microbiol. 8 (2005) 208-215
64. Cundliffe E. Antibiotic production by actinomycetes: the Janus faces of regulation. J. Ind. Microbiol. Biotechnol. 33 (2006) 500-506
65. Kiefer W., and Dannhardt G. Novel insights and therapeutical applications in the field of inhibitors of COX-2. Curr. Med. Chem. 11 (2004) 3147-3161
66. Lautru S., et al. Discovery of a new peptide natural product by Streptomyces coelicolor genome mining. Nat. Chem. Biol. 1 (2005) 265-269
67. Banskota A.H., et al. Isolation and identification of three new 5-alkenyl-3,3(2H)-furanones from two Streptomyces species using a genomic screening approach. J. Antibiot. (Tokyo) 59 (2006) 168-176
68. McAlpine J.B., et al. Microbial genomics as a guide to drug discovery and structural elucidation: ECO-02301, a novel antifungal agent, as an example. J. Nat. Prod. 68 (2005) 493-496
69. Kulanthaivel P., et al. Novel lipoglycopeptides as inhibitors of bacterial signal peptidase I. J. Biol. Chem. 279 (2004) 36250-36258
70. Mariani R., et al. Antibiotics GE23077, novel inhibitors of bacterial RNA polymerase. Part 3: chemical derivatization. Bioorg. Med. Chem. Lett. 15 (2005) 3748-3752
71. Brandi L., et al. Specific, efficient, and selective inhibition of prokaryotic translation inhibition of prokaryotic translation initiation by a novel peptide antibiotic. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 39-44
72. Watters A.A., et al. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004). J. Antimicrob. Chemother. 57 (2006) 914-923
73. Yamashita A., et al. Muraymycins, novel peptidoglycan biosynthesis inhibitors: synthesis and SAR of their analogues. Bioorg. Med. Chem. Lett. 13 (2003) 3345-3350
74. Fulco P., and Wenzel R.P. Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent. Expert Rev. Anti Infect. Ther. 4 (2006) 939-945
75. Wang J., et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441 (2006) 358-361
76. Rittenhouse S., et al. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob. Agents Chemother. 50 (2006) 3882-3885
77. Johnson A.P. Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. Curr. Opin. Investig. Drugs 8 (2007) 168-173
78. Rewcastle G.W. Becatecarin (Helsinn Healthcare). IDrugs 8 (2005) 838-847
79. Kim E.-J., and Shin W.-H. General pharmacology of CKD-732, a new anticancer agent: effects on central nervous, cardiovascular, and respiratory system. Biol. Pharm. Bull. 28 (2005) 217-223
80. Portugal J. Chartreusin, elsamicin A and related anti-cancer antibiotics. Curr. Med. Chem. Anticancer Agents 3 (2003) 411-420
81. Yeo W., et al. Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). Cancer Chemother. Pharmacol. 59 (2007) 295-300
82. Kaur G., et al. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin. Cancer Res. 10 (2004) 4813-4821
83. Stadler W.M., et al. A Phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer 5 (2006) 57-60
84. Duvic M., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109 (2007) 31-39